MetaVia Inc. Common Stock (MTVA)

• Market cap: $16.9M
• 1 day: 0.51%
• 5 days: 0.51%
• 1 month: 20.25%
• 3 months: -23.14%
• 6 months: -23.14%
• Year to date: -7.11%
• 1 year: -23.14%
• 5 years: -23.14%
• 10 years: -23.14%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

Employees: 8

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

8% more funds holding

Funds holding: 12 [Q2] → 13 (+1) [Q3]

20% less capital invested

Capital invested by funds: $4.32M [Q2] → $3.47M (-$847K) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 512% upside
• Avg. target: $12 512% upside
• High target: $12 512% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Ed Arce 42% 1-year accuracy 68 / 162 met price target

512% upside $12

Buy Initiated

30 Dec 2024